79 results on '"Bhatia, Smita"'
Search Results
2. Clinical Care for People Who Survive Childhood Cancer: A Review.
- Author
-
Bhatia, Smita, Tonorezos, Emily S., and Landier, Wendy
- Subjects
- *
CHILDHOOD cancer , *THYROID cancer , *THYROID diseases , *PITUITARY dwarfism , *CLINICAL medicine , *NEPHROBLASTOMA , *HEMATOPOIETIC stem cells - Abstract
Importance: An estimated 15 000 children and adolescents aged 0 to 19 years are diagnosed with cancer each year in the US, and more than 85% survive for at least 5 years. By 45 years of age, approximately 95% of people who survive childhood cancer will develop a significant health problem related to the childhood cancer diagnosis or its treatment. Observations: Approximately 500 000 people currently alive in the US have survived childhood cancer. The most common severe or life-threatening chronic health problems related to childhood cancer or its treatment are endocrine disorders such as hypothyroidism or growth hormone deficiency (44%), subsequent neoplasms such as breast cancer or thyroid cancer (7%), and cardiovascular disease such as cardiomyopathy or congestive heart failure, coronary artery disease, and cerebrovascular disease (5.3%). Medical conditions related to a cancer diagnosis during childhood or adolescence are most commonly caused by the radiation therapy and the chemotherapies used to treat cancer and may develop at varying lengths of time after exposure to these treatments. Individuals at highest risk for developing treatment-related health problems include patients with brain cancer treated with cranial irradiation (approximately 70% develop severe or life-threatening health problems) and allogeneic hematopoietic stem cell transplant recipients (approximately 60% develop severe or life-threatening health problems). Individuals at the lowest risk for developing treatment-related health problems include those who survived solid tumors (such as Wilms tumor) treated with surgical resection alone or with minimal chemotherapy, for whom the prevalence of subsequent health problems is similar to people who did not have cancer during childhood or adolescence. People diagnosed with childhood cancer in the 1990s who survived for at least 5 years after the cancer diagnosis have a shorter lifespan (by about 9 years) vs children who were not diagnosed with cancer in the 1990s. Conclusions and Relevance: Approximately 500 000 individuals currently alive in the US have survived childhood cancer. The most common adverse effects in individuals who survived childhood cancer are endocrine disorders, subsequent neoplasms, and cardiovascular disease. There is a need for clinicians and patients to have heightened awareness of these complications. This narrative review summarizes the current evidence regarding adverse outcomes and the optimal management of people who survive childhood cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Late Sequelae in Children with Acute Lymphoblastic Leukemia: Impact on Long-Term Survival and Quality of Life
- Author
-
Neglia, Joseph P., O’Leary, Maura, Bhatia, Smita, Reaman, Gregory H., editor, and Smith, Franklin O., editor
- Published
- 2011
- Full Text
- View/download PDF
4. Radiation (and Medical) Biosurveillance : Screening Survivors for Late Effects of Therapy Using the Children’s Oncology Group Long-Term Follow-Up Guidelines
- Author
-
Hudson, Melissa M., Landier, Wendy, Bhatia, Smita, Oeffinger, Kevin C., Sklar, Charles, Meadows, Anna, Horowitz, Marc, Poplack, David, Fordis, Michael, Constine, Louis S., Brady, L. W., editor, Heilmann, H. -P., editor, Molls, M., editor, Nieder, C., editor, Rubin, Philip, editor, Constine, Louis S., editor, Marks, Lawrence B., editor, and Okunieff, Paul, editor
- Published
- 2008
- Full Text
- View/download PDF
5. Adolescent and Young Adult Cancer Survivors: Late Effects of Treatment
- Author
-
Bhatia, Smita, Landier, Wendy, Toogood, Andrew A., Hawkins, Michael, Bleyer, W. Archie, editor, and Barr, Ronald D., editor
- Published
- 2007
- Full Text
- View/download PDF
6. Medical and Psychosocial Issues in Childhood Cancer Survivors
- Author
-
Bhatia, Smita, Landier, Wendy, Casillas, Jacqueline, Zeltzer, Lonnie, and Ganz, Patricia A., editor
- Published
- 2007
- Full Text
- View/download PDF
7. Medical and Psychosocial Issues in Childhood Cancer Survivors
- Author
-
Bhatia, Smita, Landier, Wendy, Casillas, Jacqueline, Zeltzer, Lonnie, Chang, Alfred E., editor, Hayes, Daniel F., editor, Pass, Harvey I., editor, Stone, Richard M., editor, Ganz, Patricia A., editor, Kinsella, Timothy J., editor, Schiller, Joan H., editor, and Strecher, Victor J., editor
- Published
- 2006
- Full Text
- View/download PDF
8. Severe, life‐threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood.
- Author
-
Holmqvist, Anna Sällfors, Chen, Yanjun, Hageman, Lindsey, Landier, Wendy, Wu, Jessica, Francisco, Liton F., Ross, Elizabeth Schlichting, Balas, Nora A., Bosworth, Alysia, Te, Hok Sreng, Goldman, Frederick D., Rosenthal, Joseph, Wong, F. Lennie, Weisdorf, Daniel J., Armenian, Saro H., and Bhatia, Smita
- Subjects
CHRONIC diseases ,BONE marrow transplantation ,TOTAL body irradiation ,PROPORTIONAL hazards models ,ACUTE myeloid leukemia - Abstract
Background: A comprehensive assessment of morbidity after allogeneic bone marrow transplantation (BMT) performed in childhood remains understudied. Methods: Seven hundred eighty‐nine allogeneic BMT recipients who had survived ≥2 years after BMT performed between 1974 and 2014 at age <22 years and 690 siblings completed a 255‐item survey self‐reporting sociodemographics and chronic health conditions. A severity score (grade 3 [severe], 4 [life‐threatening], or 5 [fatal]) was assigned to the conditions using Common Terminology Criteria for Adverse Events, version 5.0. For the BMT cohort, the cumulative incidence of chronic health conditions was calculated as a function of time from BMT. Proportional subdistribution hazards models were used to determine predictors of grade 3–5 conditions. Logistic regression was used to estimate the risk of grade 3–4 conditions in BMT recipients who were alive at the time of this study compared with siblings. Results: The median age at transplantation was 11.3 years (range, 0.4–22.0 years), and the median length of follow‐up was 11.7 years (range, 2.0–45.3 years). The most prevalent primary diagnoses were acute lymphoblastic leukemia (30.7%), and acute myeloid leukemia/myelodysplastic syndrome (26.9%). At age 35 years, the cumulative incidence of a grade 3–4 condition was 53.8% (95% CI, 46.7%–60.3%). The adjusted odds ratio of a grade 3–4 condition was 15.1 in survivors (95% CI, 9.5–24.0) compared with siblings. The risk of a grade 3–5 condition increased with age at BMT (hazard ratio [HR], 1.03; 95% CI, 1.01–1.05) and was higher among females (HR, 1.27; 95% CI, 1.02–1.59), patients who received total body irradiation (HR, 1.71; 95% CI, 1.27–2.31), and those reporting chronic graft‐versus‐host disease (HR, 1.38; 95% CI, 1.09–1.74). Conclusions: Two‐year survivors of allogeneic BMT in childhood have an increased risk of grade 3–4 chronic health conditions compared with siblings, suggesting the need for long‐term follow‐up. Two‐year survivors of allogeneic bone marrow transplantation in childhood have a substantially increased risk of chronic health conditions compared with siblings. By age 35 years, more than one half of bone marrow transplantation recipients had a severe or life‐threatening chronic health condition. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Psychometric Evaluation of the Impact of Cancer (IOC-CS) Scale for Young Adult Survivors of Childhood Cancer
- Author
-
Zebrack, Brad J., Donohue, Janet E., Gurney, James G., Chesler, Mark A., Bhatia, Smita, and Landier, Wendy
- Published
- 2010
- Full Text
- View/download PDF
10. Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts.
- Author
-
Richard, Melissa A., Mostoufi-Moab, Sogol, Rathore, Nisha, Baedke, Jessica, Brown, Austin L., Chanock, Stephen J., Friedman, Danielle N., Gramatges, M. Monica, Howell, Rebecca M., Kamdar, Kala Y., Leisenring, Wendy M., Meacham, Lillian R., Morton, Lindsay M., Oeffinger, Kevin, Robison, Leslie L., Sapkota, Yadav, Sklar, Charles A., Armstrong, Gregory T., Bhatia, Smita, and Lupo, Philip J.
- Subjects
CHILDHOOD cancer ,CANCER survivors ,DIABETES ,RECEIVER operating characteristic curves ,DISEASE risk factors - Abstract
PURPOSE: To characterize germline genetic risk factors of diabetes mellitus among long-term survivors of childhood cancer. METHODS: Adult survivors of childhood cancer from the Childhood Cancer Survivor Study (CCSS) Original Cohort (n = 5,083; 383 with diabetes) were used to conduct a discovery genome-wide association study. Replication was performed using the CCSS Expansion (n = 2,588; 40 with diabetes) and the St Jude Lifetime (SJLIFE; n = 3,351; 208 with diabetes) cohorts. Risk prediction models, stratified on exposure to abdominal radiation, were calculated using logistic regression including attained age, sex and body mass index, diagnosis, alkylating chemotherapy, age at cancer diagnosis, and a polygenic risk score (PRS) on the basis of 395 diabetes variants from the general population. Area under the receiver operating characteristic curve (AUC) was calculated for models on the basis of traditional risk factors, clinical risk factors, and PRS. RESULTS: There was a genome-wide significant association of rs55849673-A with diabetes among survivors (odds ratio, 2.9; 95% CI, 2.0 to 4.2; P = 3.7 × 10
−8 ), which is related to expression of ERCC6L2 in the Genotype-Tissue Expression project. The association of rs55849673-A was observed largely among survivors not exposed to abdominal radiation (odds ratio = 3.5, P = 1.1 × 10−7 ) and the frequency of rs55849673-A was consistently higher among diabetic survivors in the CCSS Expansion and SJLIFE cohorts. Risk prediction models including traditional diabetes risk factors, clinical risk factors and PRS had an optimism-corrected AUC of 0.801, with an AUC of 0.751 in survivors treated with abdominal radiation versus 0.813 in survivors who did not receive abdominal radiation. CONCLUSION: There is evidence for a novel locus of diabetes among survivors not exposed to abdominal radiation. Further refinement and validation of clinic-based risk prediction models for diabetes among long-term survivors of childhood cancer is warranted. @melissaarichard et al report germline genetic and treatment-related effects for diabetes mellitus in long-term survivors of childhood cancer. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Chronic Health Conditions in Childhood Cancer Survivors: Is it All Treatment-Related—or Do Genetics Play a Role?
- Author
-
Armenian, Saro H. and Bhatia, Smita
- Published
- 2009
- Full Text
- View/download PDF
12. Early palliative care is associated with less intense care in children dying with cancer in Alabama: A retrospective, single‐site study.
- Author
-
Davis, Elizabeth S., Martinez, Isaac, Hurst, Garrett, Bhatia, Smita, and Johnston, Emily E.
- Subjects
PALLIATIVE treatment ,HOSPICE nurses ,CHILDHOOD cancer ,CHILD death ,CANCER patient care ,TERMINAL care ,HEMATOLOGIC malignancies - Abstract
Background: Regional studies show that children with cancer receive medically intense end‐of‐life (EOL) care, but EOL care patterns, including palliative care utilization in Alabama, remain unknown. Methods: This was a retrospective study of 233 children (0‐19 years) who received cancer‐directed therapy at Children's of Alabama and died from 2010 through 2019. Rates and disparities in palliative care utilization and the association between palliative care and intense EOL care, death location, and hospice were examined. Results: The median death age was 11 years; 62% were non‐Hispanic White. Forty‐one percent had a non–central nervous system (CNS) solid tumor. Fifty‐eight percent received palliative care, and 36% received early palliative care (≥30 days before death). Children without relapsed/refractory disease were less likely to receive palliative care than those who had relapsed/refractory disease (adjusted odds ratio [aOR], 0.2; 95% confidence interval [CI], 0.1‐0.7). Children with CNS tumors and hematologic malignancies were less likely to have early palliative care (aOR for CNS tumors, 0.4; 95% CI, 0.2‐0.7; aOR for hematologic malignancies, 0.3; 95% CI, 0.2‐0.7) than children with non‐CNS solid tumors. Late palliative care (vs none) was associated with more medically intense care (aOR, 3.3; 95% CI, 1.4‐7.8) and hospital death (aOR, 4.8; 95% CI, 1.9‐11.6). Early palliative care (vs none) was associated with more hospice enrollment (aOR, 3.4; 95% CI, 1.5‐7.6) but not medically intense care (aOR, 1.3; 95% CI, 0.6‐2.9) or hospital death (aOR, 1.8; 95% CI, 0.8‐3.7). Conclusions: Fifty‐eight percent of children dying of cancer in Alabama receive palliative care, but EOL care varies with the receipt and timing (early vs late) of palliative care. Whether this variation reflects differences in child and family preferences or systemic factors (eg, hospice access) remains unknown. Pediatric cancer decedents receive intense care at the end of life. However, early palliative care reduces the intensity of end‐of‐life care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Clinical and genetic risk factors for radiation‐associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
- Author
-
Trendowski, Matthew R., Baedke, Jessica L., Sapkota, Yadav, Travis, Lois B., Zhang, Xindi, El Charif, Omar, Wheeler, Heather E., Leisenring, Wendy M., Robison, Leslie L., Hudson, Melissa M., Morton, Lindsay M., Oeffinger, Kevin C., Howell, Rebecca M., Armstrong, Gregory T., Bhatia, Smita, and Dolan, M. Eileen
- Subjects
TINNITUS ,VERTIGO ,MEDICAL personnel ,GENOME-wide association studies ,CHILDHOOD cancer ,CANCER survivors ,OTOTOXICITY ,GERIATRIC oncology ,RADIOTHERAPY safety - Abstract
BACKGROUND: Cranial radiation therapy (CRT) is associated with ototoxicity, which manifests as hearing loss and tinnitus. The authors sought to identify clinical determinants and genetic risk factors for ototoxicity among adult survivors of pediatric cancer treated with CRT. METHODS: Logistic regression evaluated associations of tinnitus (n = 1991) and hearing loss (n = 2198) with nongenetic risk factors and comorbidities among CRT‐treated survivors in the Childhood Cancer Survivor Study. Genome‐wide association studies (GWASs) of CRT‐related tinnitus and hearing loss were also performed. RESULTS: Males were more likely to report CRT‐related tinnitus (9.4% vs 5.4%; P = 5.1 × 10−4) and hearing loss (14.0% vs 10.7%; P =.02) than females. Survivors with tinnitus or hearing loss were more likely to experience persistent dizziness or vertigo (tinnitus: P < 2 × 10−16; hearing loss: P = 6.4 × 10−9), take antidepressants (tinnitus: P =.02; hearing loss: P =.01), and report poorer overall health (tinnitus: P = 1.5 × 10−6; hearing loss: P = 1.7 × 10−6) in comparison with controls. GWAS of CRT‐related tinnitus revealed a genome‐wide significant signal in chromosome 1 led by rs203248 (P = 1.5 × 10−9), whereas GWAS of CRT‐related hearing loss identified rs332013 (P = 5.8 × 10−7) in chromosome 8 and rs67522722 (P = 7.8 × 10−7) in chromosome 6 as nearly genome‐wide significant. A replication analysis identified rs67522722, intronic to ATXN1, as being significantly associated with CRT‐related hearing loss (P =.03) and de novo hearing loss (P = 3.6 × 10−4). CONCLUSIONS: CRT‐associated ototoxicity was associated with sex, several neuro‐otological symptoms, increased antidepressant use, and poorer self‐reported health. GWAS of CRT‐related hearing loss identified rs67522722, which was supported in an independent cohort of survivors. LAY SUMMARY: Hearing loss and subjective tinnitus (the perception of noise or ringing in the ear) are long‐term side effects of cancer treatment and are common in children treated with radiation to the brain.These toxicities can affect childhood development and potentially contribute to serious learning and behavioral difficulties.This study's data indicate that males are at greater risk for hearing loss and tinnitus than females after radiation therapy to the brain.Those who develop these toxicities are more likely to use antidepressants and report poorer overall health.Health care providers can improve the management of survivors by informing patients and/or their parents of these risks. Health care providers can improve the management of survivors of childhood cancer by informing patients of ototoxicity risk and associated comorbidities (dizziness and vertigo) after the completion of cranial radiation therapy. Genome‐wide association studies reveal genetic variants in ATXN1, a gene associated with spinocerebellar ataxia type 1, to be significantly associated with cranial radiation therapy–related hearing loss. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus:A report from adult life after childhood cancer in Scandinavia
- Author
-
Winther, Jeanette F, Bhatia, Smita, Cederkvist, Luise, Gudmundsdottir, Thorgerdur, Madanat-Harjuoja, Laura, Tryggvadottir, Laufey, Wesenberg, Finn, Hasle, Henrik, and Sällfors Holmqvist, Anna
- Subjects
cardiovascular disease ,diabetes mellitus ,childhood cancer ,survivorship ,cerebrovascular disease - Abstract
BACKGROUND: Childhood cancer survivors have an increased risk of cardiovascular disease (CVD) and diabetes mellitus. Because diabetes is a potentially modifiable risk factor for CVD in the general population, it is important to understand how diabetes affects the risk of CVD among childhood cancer survivors.METHODS: This study examined the risk of CVD among survivors with diabetes and 142,742 population comparison subjects. From the national cancer registries of the 5 Nordic countries, 29,324 one-year survivors of cancer diagnosed before the age of 20 years between 1968 and 2008 were identified. Study subjects were linked to the national hospital registers. The cumulative incidence of CVD was determined with competing risk methods. A Cox proportional hazards model was used to estimate the effects of diabetes and cancer on the hazard of CVD. The interaction between diabetes and cancer was analyzed.RESULTS: Diabetes was diagnosed in 324 of the 29,324 one-year survivors, and CVD was diagnosed in 2108. The hazard of diabetes was 1.7 times higher among survivors than comparison subjects (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-1.9), whereas the HR of CVD was 3.6 (95% CI, 3.3-3.8) 1 to 15 years after the cancer diagnosis and 1.9 (95% CI, 1.8-2.0) after more than 15 years. Individuals with diabetes had a 2.4 times higher hazard of CVD (95% CI, 2.1-2.8) among both survivors and comparison subjects in comparison with individuals without diabetes.CONCLUSIONS: Childhood cancer survivors with diabetes have a markedly increased risk of CVD in comparison with survivors without diabetes. However, diabetes does not increase the risk of CVD more in survivors than the general population.
- Published
- 2018
15. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
- Author
-
Kim, Jung, Gianferante, Matthew, Karyadi, Danielle M, Hartley, Stephen W, Frone, Megan N, Luo, Wen, Robison, Leslie L, Armstrong, Gregory T, Bhatia, Smita, Dean, Michael, Yeager, Meredith, Zhu, Bin, Song, Lei, Sampson, Joshua N, Yasui, Yutaka, Leisenring, Wendy M, Brodie, Seth A, Andrade, Kelvin C de, Fortes, Fernanda P, and Goldstein, Alisa M
- Subjects
CHILDHOOD cancer ,CANCER survivors - Abstract
Background Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study. Methods Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons. Results Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided P = 3 × 10
-4 ). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including BRCA1/2 , FH , PALB2 , PMS2 , and CDKN2A. A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (NF1 , SUFU , TSC1 , PTCH2), Wilms tumor (WT1 , REST), non-Hodgkin lymphoma (PMS2), and soft tissue sarcomas (SDHB , DICER1 , TP53 , ERCC4 , FGFR3) compared with other pediatric cancers. Conclusion In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Survival of Childhood Cancer and Subsequent Clinical Care—Reply.
- Author
-
Bhatia, Smita, Tonorezos, Emily S., and Landier, Wendy
- Subjects
- *
CHILDHOOD cancer , *CLINICAL medicine - Published
- 2024
- Full Text
- View/download PDF
17. Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
- Author
-
Richard, Melissa A., Brown, Austin L., Belmont, John W., Scheurer, Michael E., Arroyo, Vidal M., Foster, Kayla L., Kern, Kathleen D., Hudson, Melissa M., Leisenring, Wendy M., Okcu, M. Fatih, Sapkota, Yadav, Yasui, Yutaka, Morton, Lindsay M., Chanock, Stephen J., Robison, Leslie L., Armstrong, Gregory T., Bhatia, Smita, Oeffinger, Kevin C., Lupo, Philip J., and Kamdar, Kala Y.
- Subjects
LYMPHOBLASTIC leukemia ,BODY mass index ,CHILDHOOD cancer ,ACUTE leukemia ,CANCER survivors ,GENETIC correlations - Abstract
Background: Treatment characteristics such as cranial radiation therapy (CRT) do not fully explain adiposity risk in childhood acute lymphoblastic leukemia (ALL) survivors. This study was aimed at characterizing genetic variation related to adult body mass index (BMI) among survivors of childhood ALL. Methods: Genetic associations of BMI among 1458 adult survivors of childhood ALL (median time from diagnosis, 20 years) were analyzed by multiple approaches. A 2‐stage genome‐wide association study in the Childhood Cancer Survivor Study (CCSS) and the St. Jude Lifetime Cohort Study (SJLIFE) was performed. BMI was a highly polygenic trait in the general population. Within the known loci, the BMI percent variance explained was estimated, and additive interactions (chi‐square test) with CRT in the CCSS were evaluated. The role of DNA methylation in CRT interaction was further evaluated in a subsample of ALL survivors. Results: In a meta‐analysis of the CCSS and SJLIFE, 2 novel loci associated with adult BMI among survivors of childhood ALL (LINC00856 rs575792008 and EMR1 rs62123082; PMeta < 5E–8) were identified. It was estimated that the more than 700 known loci explained 6.2% of the variation in adult BMI in childhood ALL survivors. Within the known loci, significant main effects for 23 loci and statistical interactions with CRT at 9 loci (P < 7.0E–5) were further identified. At 2 CRT‐interacting loci, DNA methylation patterns may have differed by age. Conclusions: Adult survivors of childhood ALL have genetic heritability for BMI similar to that observed in the general population. This study provides evidence that treatment with CRT can modify the effect of genetic variants on adult BMI in childhood ALL survivors. Adult survivors of childhood acute lymphoblastic leukemia, particularly those treated with cranial radiation, are at increased risk for obesity. This study provides evidence that the body mass index in adult survivors of childhood acute lymphoblastic leukemia is a genetically heritable trait similar to that in the general population and that the effect of genetic loci from the general population may be modified by treatment with cranial radiation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report.
- Author
-
Singh, Purnima, Wang, Xuexia, Hageman, Lindsey, Chen, Yanjun, Magdy, Tarek, Landier, Wendy, Ginsberg, Jill P., Neglia, Joseph P., Sklar, Charles A., Castellino, Sharon M., Dreyer, Zoann E., Hudson, Melissa M., Robison, Leslie L., Blanco, Javier G., Relling, Mary V., Burridge, Paul, and Bhatia, Smita
- Subjects
CHILDHOOD cancer ,CARDIOMYOPATHIES ,CANCER survivors ,DELETION mutation ,PLURIPOTENT stem cells ,RADIATION carcinogenesis - Abstract
Background: Anthracycline-related cardiomyopathy is a leading cause of late morbidity in childhood cancer survivors. Glutathione S-transferases (GSTs) are a class of phase II detoxification enzymes that facilitate the elimination of anthracyclines. As free-radical scavengers, GSTs could play a role in oxidative damage-induced cardiomyopathy. Associations between the GSTμ1 (GSTM1) null genotype and iron-overload-related cardiomyopathy have been reported in patients with thalassemia.Methods: The authors sought to identify an association between the GSTM1 null genotype and anthracycline-related cardiomyopathy in childhood cancer survivors and to corroborate the association by examining GSTM1 gene expression in peripheral blood and human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) from survivors with and without cardiomyopathy. GSTM1 gene deletion was examined by polymerase chain reaction in 75 survivors who had clinically validated cardiomyopathy (cases) and in 92 matched survivors without cardiomyopathy (controls). Conditional logistic regression analysis adjusting for sex, age at cancer diagnosis, chest radiation, and anthracycline dose was used to assess the association between genotype and cardiomyopathy. Proprietary bead array technology and quantitative real-time polymerase chain reaction were used to measure GSTM1 expression levels in samples from 20 cases and 20 matched controls. hiPSC-CMs from childhood cancer survivors (3 with cardiomyopathy, 3 without cardiomyopathy) also were examined for GSTM1 gene expression levels.Results: A significant association was observed between the risk of cardiomyopathy and the GSTM1 null genotype (odds ratio, 2.7; 95% CI, 1.3-5.9; P = .007). There was significant downregulation of GSTM1 expression in cases compared with controls (average relative expression, 0.67 ± 0.57 vs 1.33 ± 1.33, respectively; P = .049). hiPSC-CMs from patients who had cardiomyopathy revealed reduced GSTM1 expression (P = .007).Conclusions: The current findings could facilitate the identification of childhood cancer survivors who are at risk for anthracycline-related cardiomyopathy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. Bereaved parents' views on end-of-life care for children with cancer: Quality marker implications.
- Author
-
Johnston, Emily E., Molina, Jannelle, Martinez, Isaac, Dionne‐Odom, J. Nicholas, Currie, Erin R., Crowl, Terra, Butterworth, Lori, Chamberlain, Lisa J., Bhatia, Smita, Rosenberg, Abby R., and Dionne-Odom, J Nicholas
- Subjects
CHILDHOOD cancer ,PARENT attitudes ,TUMOR markers ,TERMINAL care ,HOSPICE nurses ,PARENTS ,PEDIATRIC hematology - Abstract
Background: End-of-life (EOL) quality markers in adult oncology include home death and intensive care unit avoidance. Corresponding markers are lacking in pediatric oncology. This study was aimed at describing bereaved parents' perspectives of high-quality EOL care in pediatric oncology.Methods: This study enrolled a convenience sample of 28 bereaved parents (English- or Spanish-speaking) whose children (0-21 years old) had died of cancer ≥6 months before. Semistructured interviews were conducted to elicit parental perceptions of medically intense/quality EOL care. Interviews were recorded and transcribed verbatim (30 hours), and study team consensus and content analyses identified themes related to EOL quality markers. Related quotes were scored on a 5-point Likert scale ranging from 1 (supported comfort care) to 5 (supported medically aggressive care).Results: The children died in 1998-2017 at a mean age of 10 years (SD, 5.2 years); 50% had a solid tumor, and 46% were Spanish-speaking. Themes included 1) home death preference (unless home support was inadequate; median score, 1.6), nonaggressive care (median score, 2.4), and continued anticancer therapy (median score, 3.2); 2) programs/policies that could alleviate barriers limiting a family's time with a dying child (visiting restrictions and financial strains); 3) the need to prepare the family for death (eg, what would happen to the child's body), and 4) perceived abandonment.Conclusions: This is the first qualitative study to identify quality makers for children dying of cancer from bereaved parents' perspectives. Natural death is generally preferred, and quality measures that address barriers to parents' spending time with their children, a lack of preparation for the events surrounding death, and feelings of abandonment are critical. Future studies need to validate these findings and develop targeted interventions. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
20. Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study.
- Author
-
Richard, Melissa A., Lupo, Philip J., Morton, Lindsay M., Yasui, Yutaka A., Sapkota, Yadav A., Arnold, Michael A., Aubert, Geraldine, Neglia, Joseph P., Turcotte, Lucie M., Leisenring, Wendy M., Sampson, Joshua N., Chanock, Stephen J., Hudson, Melissa M., Armstrong, Gregory T., Robison, Leslie L., Bhatia, Smita, and Gramatges, Maria Monica
- Subjects
TELOMERES ,CHILDHOOD cancer ,CANCER patients ,TUMORS ,CANCER ,B cells ,THYROTROPIN - Abstract
Background: Telomere length is associated with risk for thyroid subsequent malignant neoplasm in survivors of childhood cancer. Here, we investigated associations between thyroid subsequent malignant neoplasm and inherited variation in telomere maintenance genes. Methods: We used RegulomeDB to annotate the functional impact of variants mapping to 14 telomere maintenance genes among 5,066 five-or-more year survivors who participate in the Childhood Cancer Survivor Study (CCSS) and who are longitudinally followed for incidence of subsequent cancers. Hazard ratios for thyroid subsequent malignant neoplasm were calculated for 60 putatively functional variants with minor allele frequency ≥1% in or near telomere maintenance genes. Functional impact was further assessed by measuring telomere length in leukocyte subsets. Results: The minor allele at Protection of Telomeres-1 (POT1) rs58722976 was associated with increased risk for thyroid subsequent malignant neoplasm (adjusted HR = 6.1, 95% CI: 2.4, 15.5, P = 0.0001; Fisher's exact P = 0.001). This imputed SNP was present in three out of 110 survivors who developed thyroid cancer vs. 14 out of 4,956 survivors who did not develop thyroid cancer. In a subset of 83 survivors with leukocyte telomere length data available, this variant was associated with longer telomeres in B lymphocytes (P = 0.004). Conclusions: Using a functional variant approach, we identified and confirmed an association between a low frequency intronic regulatory POT1 variant and thyroid subsequent malignant neoplasm in survivors of childhood cancer. These results suggest that intronic variation in POT1 may affect key protein binding interactions that impact telomere maintenance and genomic integrity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Comparison of Radiation Dose Reconstruction Methods to Investigate Late Adverse Effects of Radiotherapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study.
- Author
-
Schonfeld, Sara J., Howell, Rebecca M., Smith, Susan A., Neglia, Joseph P., Turcotte, Lucie M., Arnold, Michael A., Inskip, Peter D., Oeffinger, Kevin C., Moskowitz, Chaya S., Henderson, Tara O., Leisenring, Wendy M., Gibson, Todd M., de González, Amy Berrington, Sampson, Joshua N., Chanock, Stephen J., Tucker, Margaret A., Bhatia, Smita, Robison, Leslie L., Armstrong, Gregory T., and Morton, Lindsay M.
- Subjects
CHILDHOOD cancer ,RADIATION doses ,CANCER patients ,CANCER radiotherapy ,BRAIN tumors ,BREAST cancer prognosis ,COHEN'S kappa coefficient (Statistics) ,BREAST - Abstract
Quantification of radiation dose to normal tissue during radiotherapy is critical for assessing risk for radiotherapy-related late effects, including subsequent neoplasms (SNs). Case-control studies of SNs typically reconstruct absorbed radiation dose to the specific SN location using individual treatment parameters. A simplified method estimates the maximum prescribed target dose to the body region in which the SN arises. We compared doses and risk estimates from these methods using data from case-control studies of subsequent brain tumors (64 cases, 244 controls) and breast cancer (94 cases, 358 controls) nested within the Childhood Cancer Survivor Study (≥5-year survivors of childhood cancer diagnosed 1970–1986). The weighted kappa statistic [95% confidence interval (CI)] evaluating agreement between categorical (>0–9.9/10–19.9/20–29.9/≥30 Gy) body-region and tumor location-specific doses was 0.95 (0.91–0.98) for brain and 0.76 (0.69–0.82) for breast. The body-region and location-specific doses were assigned to the same dose category for a smaller proportion of patients treated with fields delivering a heterogeneous dose across the tissue of interest (e.g., partial brain field = 57.1%; mantle field = 61.3%) than patients treated with fields delivering a more homogeneous dose (e.g., whole brain field = 100%). Excess odds ratios per Gy (95% CI) from conditional logistic regression were 1.25 (0.33–6.33) and 1.20 (0.31–6.14) for brain tumors and 0.21 (0.05–0.77) and 0.10 (0.02–0.44) for breast cancer, using location-specific and body-region doses, respectively. We observed that body-region doses can approximate location-specific doses when the tissue of interest is clearly in the radiation field or outside the treated body region. Agreement is lower when there is greater ambiguity of SN location relative to the treatment field. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Providing health care for patients with childhood cancer and survivors: A survey of pediatric primary care providers.
- Author
-
Wadhwa, Aman, Chen, Yanjun, Bhatia, Smita, and Landier, Wendy
- Subjects
ONCOLOGISTS ,CANCER patient care ,ACUTE medical care ,PRIMARY care ,ATTITUDES of medical personnel ,CHILDHOOD cancer ,IMMUNIZATION ,SELF-confidence - Abstract
Background: The current study was conducted to assess self-reported comfort levels of pediatric primary care providers (PCPs) in providing acute medical care to patients with childhood cancer who currently were receiving therapy (on-therapy patients) and health maintenance care to childhood cancer survivors, independently and in conjunction with pediatric oncologists, along with confidence levels regarding knowledge about immunizations for survivors. All levels were measured using 7-point Likert scales.Methods: A cross-sectional, 23-item survey mailed to practicing PCPs affiliated with a tertiary children's hospital was analyzed.Results: The response rate was 64.4% (259 of 402 eligible PCPs). The mean PCP comfort level was higher when collaborating with a pediatric oncologist to provide acute medical care for on-therapy patients and health maintenance care for childhood cancer survivors (mean ratings of 6.0 ± 1.5 and 6.4 ± 1.3, respectively) compared with independently providing such care (mean ratings of 4.6 ± 1.8 and 5.0 ± 1.7, respectively; P < .0001). Only approximately 30% of PCPs were confident in their knowledge regarding immunizations for survivors. Certain factors were found to be associated with PCP comfort in providing care in conjunction with a pediatric oncologist. For acute care, these factors were rural location compared with urban location (odds ratio [OR], 5.0; 95% CI, 1.9-13.1 [P = .03]) and having cared for ≥6 on-therapy patients within the past year versus none (OR, 3.8; 95% CI, 1.9-7.5 [P = .0001]). For survivor health maintenance care, practice location <50 miles from pediatric oncology specialty care versus ≥50 miles was the only factor found to be associated with PCP comfort (OR, 2.8; 95% CI, 1.3-6.1 [P = .009]).Conclusions: The findings of the current study underscore the need for collaboration between pediatric oncologists and PCPs when caring for children with cancer across the spectrum of care. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
23. Racial and ethnic disparities in neurocognitive, emotional, and quality-of-life outcomes in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
- Author
-
Dixon, Stephanie B., Li, Nan, Yasui, Yutaka, Bhatia, Smita, Casillas, Jacqueline N., Gibson, Todd M., Ness, Kirsten K., Porter, Jerlym S., Howell, Rebecca M., Leisenring, Wendy M., Robison, Leslie L., Hudson, Melissa M., Krull, Kevin R., and Armstrong, Gregory T.
- Subjects
CHILDHOOD cancer ,CANCER patients ,QUALITY of life ,ETHNIC groups ,DEMOGRAPHIC characteristics ,ETHNIC differences - Abstract
Background: Survivors of childhood cancer are at risk of neurocognitive impairment, emotional distress, and poor health-related quality of life (HRQOL); however, the effect of race/ethnicity is understudied. The objective of this study was to identify race/ethnicity-based disparities in neurocognitive, emotional, and HRQOL outcomes among survivors of childhood cancer.Methods: Self-reported measures of neurocognitive function, emotional distress (the Brief Symptom Inventory-18), and HRQOL (the Medical Outcomes Study Short Form-36 health survey) were compared between minority (Hispanic, n = 821; non-Hispanic black [NHB], n = 600) and non-Hispanic white (NHW) (n = 12,287) survivors from the Childhood Cancer Survivor Study (median age, 30.9 years; range, 16.0-54.1 years). By using a sample of 3055 siblings, the magnitude of same-race/same-ethnicity survivor-sibling differences was compared between racial/ethnic groups, adjusting for demographic and treatment characteristics and current socioeconomic status (SES).Results: No clear pattern of disparity in neurocognitive outcomes by race/ethnicity was observed. The magnitude of the survivor-sibling difference in the mean score for depression was greater in Hispanics than in NHWs (3.59 vs 1.09; P = .004). NHBs and Hispanics had greater survivor-sibling differences in HRQOL than NHWs for mental health (NHBs: -5.78 vs -0.69; P = .001; Hispanics: -3.87 vs -0.69; P = .03), and social function (NHBs: -7.11 vs -1.47; P < .001; Hispanics: -5.33 vs -1.47; P = .001). NHBs had greater survivor-sibling differences in physical subscale scores for HRQOL than NHWs. In general, the findings were not attenuated by current SES.Conclusions: Although no pattern of disparity in neurocognitive outcomes was observed, differences across many HRQOL outcomes among minorities compared with NHWs, not attenuated by current SES, were identified. This suggests that further research into environmental and sociocultural factors during and immediately after treatment is needed. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
24. Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: A report from adult life after childhood cancer in Scandinavia.
- Author
-
Winther, Jeanette F., Bhatia, Smita, Cederkvist, Luise, Gudmundsdottir, Thorgerdur, Madanat‐Harjuoja, Laura, Tryggvadottir, Laufey, Wesenberg, Finn, Hasle, Henrik, Sällfors Holmqvist, Anna, Madanat-Harjuoja, Laura, and ALiCCS Study Group
- Subjects
- *
CARDIOVASCULAR diseases , *CARDIOVASCULAR diseases risk factors , *CHILDHOOD cancer , *DIABETES , *PROGRESSION-free survival - Abstract
Background: Childhood cancer survivors have an increased risk of cardiovascular disease (CVD) and diabetes mellitus. Because diabetes is a potentially modifiable risk factor for CVD in the general population, it is important to understand how diabetes affects the risk of CVD among childhood cancer survivors.Methods: This study examined the risk of CVD among survivors with diabetes and 142,742 population comparison subjects. From the national cancer registries of the 5 Nordic countries, 29,324 one-year survivors of cancer diagnosed before the age of 20 years between 1968 and 2008 were identified. Study subjects were linked to the national hospital registers. The cumulative incidence of CVD was determined with competing risk methods. A Cox proportional hazards model was used to estimate the effects of diabetes and cancer on the hazard of CVD. The interaction between diabetes and cancer was analyzed.Results: Diabetes was diagnosed in 324 of the 29,324 one-year survivors, and CVD was diagnosed in 2108. The hazard of diabetes was 1.7 times higher among survivors than comparison subjects (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-1.9), whereas the HR of CVD was 3.6 (95% CI, 3.3-3.8) 1 to 15 years after the cancer diagnosis and 1.9 (95% CI, 1.8-2.0) after more than 15 years. Individuals with diabetes had a 2.4 times higher hazard of CVD (95% CI, 2.1-2.8) among both survivors and comparison subjects in comparison with individuals without diabetes.Conclusions: Childhood cancer survivors with diabetes have a markedly increased risk of CVD in comparison with survivors without diabetes. However, diabetes does not increase the risk of CVD more in survivors than the general population. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy.
- Author
-
Brooke, Russell J, Im, Cindy, Wilson, Carmen L, Krasin, Matthew J, Liu, Qi, Li, Zhenghong, Sapkota, Yadav, Moon, WonJong, Morton, Lindsay M, Wu, Gang, Wang, Zhaoming, Chen, Wenan, Howell, Rebecca M, Armstrong, Gregory T, Bhatia, Smita, Mostoufi-Moab, Sogol, Seidel, Kristy, Chanock, Stephen J, Zhang, Jinghui, and Green, Daniel M
- Subjects
CHILDHOOD cancer ,TUMORS in children ,CANCER patients ,PREMATURE menopause ,MENOPAUSE ,ANTINEOPLASTIC agents ,COMPARATIVE studies ,GENETIC polymorphisms ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,OVARIES ,OVARIAN diseases ,RADIATION injuries ,RADIOTHERAPY ,RESEARCH ,TUMORS ,EVALUATION research ,CASE-control method ,HAPLOTYPES ,SEQUENCE analysis ,PHYSIOLOGICAL effects of radiation - Abstract
Background: Childhood cancer survivors are at increased risk of therapy-related premature menopause (PM), with a cumulative incidence of 8.0%, but the contribution of genetic factors is unknown.Methods: Genome-wide association analyses were conducted to identify single nucleotide polymorphisms (SNPs) associated with clinically diagnosed PM (menopause < 40 years) among 799 female survivors of childhood cancer participating in the St. Jude Lifetime Cohort Study (SJLIFE). Analyses were adjusted for cyclophosphamide equivalent dose of alkylating agents and ovarian radiotherapy (RT) dose (all P values two-sided). Replication was performed using self-reported PM in 1624 survivors participating in the Childhood Cancer Survivor Study (CCSS).Results: PM was clinically diagnosed in 30 (3.8%) SJLIFE participants. Thirteen SNPs (70 kb region of chromosome 4q32.1) upstream of the Neuropeptide Receptor 2 gene (NPY2R) were associated with PM prevalence (minimum P = 3.3 × 10-7 for rs9999820, all P < 10-5). Being a homozygous carrier of a haplotype formed by four of the 13 SNPs (seen in one in seven in the general population but more than 50% of SJLIFE clinically diagnosed PM) was associated with markedly elevated PM prevalence among survivors exposed to ovarian RT (odds ratio [OR] = 25.89, 95% confidence interval [CI] = 6.18 to 138.31, P = 8.2 × 10-6); this finding was replicated in an independent second cohort of CCSS in spite of its use of self-reported PM (OR = 3.97, 95% CI = 1.67 to 9.41, P = .002). Evidence from bioinformatics data suggests that the haplotype alters the regulation of NPY2R transcription, possibly affecting PM risk through neuroendocrine pathways.Conclusions: The haplotype captures the majority of clinically diagnosed PM cases and, with further validation, may have clinical application in identifying the highest-risk survivors for PM for possible intervention by cryopreservation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors.
- Author
-
Bosworth, Alysia, Goodman, Elizabeth L., Wu, Eric, Francisco, Liton, Robison, Leslie L., and Bhatia, Smita
- Subjects
QUALITY of life ,CANCER patients ,CHILDHOOD cancer ,CANCER treatment ,PRINCIPAL components analysis ,EXPERIMENTAL design ,FACTOR analysis ,RESEARCH methodology ,PSYCHOMETRICS ,QUESTIONNAIRES ,RESEARCH evaluation ,STATISTICAL reliability ,MULTITRAIT multimethod techniques ,RESEARCH methodology evaluation ,DATA analysis software - Abstract
Purpose: Childhood cancer survivors are at risk for deficits in health-related quality of life (HRQL) as they age. Youth (8-12 years) and adolescent (13-20 years) versions of the Minneapolis-Manchester Quality of Life Instrument (MMQL) have been developed to address survivor-specific issues and are currently in use; the MMQL-Adult Form has now been developed to assess HRQL in childhood cancer survivors aged 21-55 years.Methods: The MMQL-Adult Form was administered to 499 adults: 65 cancer patients on-therapy, 107 off-therapy, and 327 healthy controls. Forty-four percent of patients were under 30 years old at cancer diagnosis. Principal components analysis was performed. We evaluated internal consistency reliability, stability (re-administration of the MMQL-Adult Form 2 weeks later), construct validity (concurrent administration of the SF-36), and known-groups validity (score comparisons across the three groups).Results: Principal components analysis resulted in retention of 44 items across six scales: social functioning, physical functioning, cognitive functioning, outlook on life, body image, and psychological functioning. Internal consistency (Cronbach's α) was 0.80-0.90 for individual scales and 0.95 overall. Strong intraclass correlations (0.98 overall) indicated high stability. The MMQL-Adult Form distinguished between known groups; healthy controls scored better than patients on four of six scales. The MMQL-Adult Form scales correlated highly with similar SF-36 scales, demonstrating construct validity.Conclusions: The MMQL-Adult Form is a reliable and valid self-report instrument for measuring multidimensional HRQL in cancer survivors. Development of this instrument ensures availability of a tool enabling cross-sectional and longitudinal assessment of HRQL in childhood cancer survivors as they age. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. Evidence for Genetic Risk Contributing to Long-Term Adverse Treatment Effects in Childhood Cancer Survivors.
- Author
-
Gramatges, Maria Monica and Bhatia, Smita
- Abstract
Survivors of childhood cancer are at increased risk for therapy-related morbidities and mortality. Although the demographic and clinical factors predicting the risk for long-term effects of cancer therapy are well known, the impact of genetic risk for specific late effects is less clearly defined. Here, we review the extant literature and recent research describing genetic modifiers to risk for the more common late effects of childhood cancer therapy. Results of this research support the need for clinical trials that attempt to further refine risk prediction by incorporating genetic testing into existing algorithms that are primarily based on clinical and demographic factors. Confirmation of genetic predisposition, as defined by reproducibility and prospective validation, would permit therapeutic modification and discussion of individualized survivor care plans even at initial cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients.
- Author
-
Landier, Wendy, Ahern, JoAnn, Barakat, Lamia P., Bhatia, Smita, Bingen, Kristin M., Bondurant, Patricia G., Cohn, Susan L., Dobrozsi, Sarah K., Haugen, Maureen, Herring, Ruth Anne, Hooke, Mary C., Martin, Melissa, Murphy, Kathryn, Newman, Amy R., Rodgers, Cheryl C., Ruccione, Kathleen S., Sullivan, Jeneane, Weiss, Marianne, Withycombe, Janice, and Yasui, Lise
- Abstract
There is a paucity of data to support evidence-based practices in the provision of patient/family education in the context of a new childhood cancer diagnosis. Since the majority of children with cancer are treated on pediatric oncology clinical trials, lack of effective patient/family education has the potential to negatively affect both patient and clinical trial outcomes. The Children’s Oncology Group Nursing Discipline convened an interprofessional expert panel from within and beyond pediatric oncology to review available and emerging evidence and develop expert consensus recommendations regarding harmonization of patient/family education practices for newly diagnosed pediatric oncology patients across institutions. Five broad principles, with associated recommendations, were identified by the panel, including recognition that (1) in pediatric oncology, patient/family education is family-centered; (2) a diagnosis of childhood cancer is overwhelming and the family needs time to process the diagnosis and develop a plan for managing ongoing life demands before they can successfully learn to care for the child; (3) patient/family education should be an interprofessional endeavor with 3 key areas of focus: (a) diagnosis/treatment, (b) psychosocial coping, and (c) care of the child; (4) patient/family education should occur across the continuum of care; and (5) a supportive environment is necessary to optimize learning. Dissemination and implementation of these recommendations will set the stage for future studies that aim to develop evidence to inform best practices, and ultimately to establish the standard of care for effective patient/family education in pediatric oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure
- Author
-
Armenian, Saro H., Hudson, Melissa M., Ming Hui Chen, Colan, Steven D., Lindenfeld, Lanie, Mills, George, Siyahian, Aida, Gelehrter, Sarah, Ha Dang, Hein, Wendy, Green, Daniel M., Robison, Leslie L., Wong, F. Lennie, Douglas, Pamela S., and Bhatia, Smita
- Subjects
ANTHRACYCLINES ,CHILDHOOD cancer ,CARDIOMYOPATHIES ,HEART failure ,CARVEDILOL ,THERAPEUTICS ,CANCER treatment - Abstract
Background: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the efficacy of low-dose beta-blocker (carvedilol) for HF risk reduction in childhood cancer survivors at highest risk for HF. The proposed intervention has the potential to significantly reduce chronic cardiac injury via interruption of neurohormonal systems responsible for left ventricular (LV) remodeling, resulting in improved cardiac function and decreased risk of HF. The intervention is informed by previous studies demonstrating efficacy in pediatric and adult non-oncology populations, yet remains unstudied in the pediatric oncology population. Methods/Design: The primary objective of the trial is to determine impact of the intervention on echocardiographic markers of cardiac remodeling and HF risk, including: LV wall thickness/ dimension ratio (LVWT/D; primary endpoint), as well as LV ejection fraction, volume, and blood biomarkers (natriuretic peptides, galectin-3) associated with HF risk. Secondary objectives are to establish safety and tolerability of the 2-year course of carvedilol using: 1) objective measures: hepatic and cardiovascular toxicity, treatment adherence, and 2) subjective measures: participant self-reported outcomes. Two hundred and fifty survivors of childhood cancer (diagnosed <21 years of age), and previously treated with high-dose (≥300 mg/m
2 ) anthracyclines will be enrolled in a randomized, doubleblind, placebo controlled trial. After baseline assessments, participants will be randomized in a 1:1 ratio to low-dose carvedilol (maximum dose: 12.5 mg/day) or placebo. Carvedilol or placebo is up-titrated (starting dose: 3. 125 mg/day) according to tolerability. Discussion: When completed, this study will provide much-needed information regarding a physiologically plausible pharmacological risk-reduction strategy for childhood cancer survivors at high risk for developing anthracycline-related HF. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
30. Childhood cancer survivorship research in minority populations: A position paper from the Childhood Cancer Survivor Study.
- Author
-
Bhatia, Smita, Gibson, Todd M., Ness, Kirsten K., Liu, Qi, Oeffinger, Kevin C., Krull, Kevin R., Nathan, Paul C., Neglia, Joseph P., Leisenring, Wendy, Yasui, Yutaka, Robison, Leslie L., and Armstrong, Gregory T.
- Subjects
- *
CHILDHOOD cancer , *CANCER patients , *ETHNIC groups , *EARLY death , *TUMORS in children - Abstract
By the middle of this century, racial/ethnic minority populations will collectively constitute 50% of the US population. This temporal shift in the racial/ethnic composition of the US population demands a close look at the race/ethnicity-specific burden of morbidity and premature mortality among survivors of childhood cancer. To optimize targeted long-term follow-up care, it is essential to understand whether the burden of morbidity borne by survivors of childhood cancer differs by race/ethnicity. This is challenging because the number of minority participants is often limited in current childhood cancer survivorship research, resulting in a paucity of race/ethnicity-specific recommendations and/or interventions. Although the overall childhood cancer incidence increased between 1973 and 2003, the mortality rate declined; however, these changes did not differ appreciably by race/ethnicity. The authors speculated that any racial/ethnic differences in outcome are likely to be multifactorial, and drew on data from the Childhood Cancer Survivor Study to illustrate the various contributors (socioeconomic characteristics, health behaviors, and comorbidities) that could explain any observed differences in key treatment-related complications. Finally, the authors outlined challenges in conducting race/ethnicity-specific childhood cancer survivorship research, demonstrating that there are limited absolute numbers of children who are diagnosed and survive cancer in any one racial/ethnic minority population, thereby precluding a rigorous evaluation of adverse events among specific primary cancer diagnoses and treatment exposure groups. Cancer 2016;122:2426-2439. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Looking back to inform the future: Lesson learned from survivors of childhood cancer.
- Author
-
Armenian, Saro H. and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *CANCER , *CANCER research , *RETINOBLASTOMA , *TUMORS , *VISION disorders , *PATIENTS , *BLINDNESS , *GLIOMAS , *CATARACT , *HEARING impaired children , *THYROID gland tumors , *RETINA , *SECONDARY primary cancer , *PSYCHOLOGY ,CENTRAL nervous system tumors - Abstract
Long‐term survival is an expected outcome for children diagnosed with retinoblastoma and low‐grade astroglial tumors. Studies examining health‐related outcomes in long‐term survivors of these malignancies can help inform the next‐generation therapeutic studies aimed at decreasing long‐term morbidity without compromising survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. Parent-Directed Intervention for Children With Cancer-Related Neurobehavioral Late Effects: A Randomized Pilot Study.
- Author
-
Patel, Sunita K., Ross, Paula, Cuevas, Michelle, Turk, Anne, Kim, Heeyoung, Lo, Tracy T. Y., Wong, Lennie F., and Bhatia, Smita
- Subjects
CHILDHOOD cancer ,NEUROBEHAVIORAL disorders ,CANCER patient psychology ,PARENT-child relationships & psychology ,TREATMENT effectiveness ,CANCER treatment - Abstract
Objective To evaluate feasibility and preliminary efficacy of an intervention directed at parents of childhood cancer survivors (CCSs) with neurobehavioral late effects to improve targeted parenting skills, and thus to indirectly benefit the child’s educational functioning. Methods 44 CCSs and their parents were randomized. Intervention-arm parents participated in eight individual training sessions augmented by a 3-month telephone support period. Pre- and postparent measures and child performance on Wechsler Individual Achievement Test-II and School Motivation and Learning Strategies Inventory assessed intervention effects. Results 90% of intervention parents completed the program with high adherence/perceived benefit. Between-group effect sizes ranged from d = 0.77 to d = 1.45 for parent knowledge, efficacy, frequency of pro-learning behaviors, and d = 0.21 to d = 0.76 for child academic scores. Parental time spent in intervention activities was associated with academic change. Conclusions A parent-directed intervention to indirectly promote academic functioning in CCSs appears feasible and effective in improving targeted parenting outcomes and for selected child academic outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors at Risk for Treatment-Related Heart Failure.
- Author
-
Wong, F. Lennie, Bhatia, Smita, Landier, Wendy, Francisco, Liton, Leisenring, Wendy, Hudson, Melissa M., Armstrong, Gregory T., Mertens, Ann, Stovall, Marilyn, Robison, Leslie L., Lyman, Gary H., Lipshultz, Steven E., and Armenian, Saro H.
- Subjects
- *
ANTHRACYCLINES , *CHILDHOOD cancer , *HEART failure in children , *QUALITY-adjusted life years , *ECHOCARDIOGRAPHY , *PREVENTION , *CANCER treatment - Abstract
Background: Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. Objective: To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Design: Simulation of life histories using Markov health states. Data Sources: Childhood Cancer Survivor Study; published literature. Target Population: Childhood cancer survivors. Time Horizon: Lifetime. Perspective: Societal. Intervention: Echocardiographic screening followed by angiotensin-converting enzyme (ACE) inhibitor and β-blocker therapies after ALVD diagnosis. Outcome Measures: Quality-adjusted life-years (QALYs), costs, incremental cost-effectiveness ratios (ICERs) in dollars per QALY, and cumulative incidence of heart failure. Results of Base-Case Analysis: The COG guidelines versus no screening have an ICER of $61 500, extend life expectancy by 6 months and QALYs by 1.6 months, and reduce the cumulative incidence of heart failure by 18% at 30 years after cancer diagnosis. However, less frequent screenings are more cost-effective than the guidelines and maintain 80% of the health benefits. Results of Sensitivity Analysis: The ICER was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER. Limitation: Lifetime non-heart failure mortality and the cumulative incidence of heart failure more than 20 years after diagnosis were extrapolated; the efficacy of ACE inhibitor and β-blocker therapy in childhood cancer survivors with ALVD is undetermined (or unknown). Conclusion: The COG guidelines could reduce the risk for heart failure in survivors at less than $100 000/QALY. Less frequent screening achieves most of the benefits and would be more cost-effective than the COG guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Transitioning childhood cancer survivors to adult-centered healthcare: insights from parents, adolescent, and young adult survivors.
- Author
-
Casillas, Jacqueline, Kahn, Katherine L., Doose, Michelle, Landier, Wendy, Bhatia, Smita, Hernandez, Joanna, and Zeltzer, Lonnie K.
- Subjects
CHILDHOOD cancer ,CANCER patients ,HISPANIC Americans ,YOUNG adults ,SOCIAL stigma ,ONCOLOGY - Abstract
Objective: To determine Latino adolescent and young adults (AYA) cancer survivors' perceived barriers or facilitators to transition from pediatric to adult-centered survivorship care and to also assess the parents' perspective of care. Methods: Partnering with a community-based organization that serves Latino survivors, we conducted a qualitative, constant comparative analytic approach exploring in-depth themes that have salience for Latino pediatric cancer survivors seeking care in the adult healthcare setting. Twenty-seven Latino AYA survivors (⩾15 years of age) completed key informant interviews and 21 Latino parents participated in focus groups. Results: Both AYA survivors and parents identified two major facilitative factors for survivorship care: Involvement of the nuclear family in the AYA's survivorship care in the adult healthcare setting and including symptom communication in late effects discussions. Barriers to care included: perceived stigma of a cancer history and continued emotional trauma related to discussions about the childhood cancer experience. Conclusions: Barriers to survivorship care include cancer stigma for both patient and nuclear family, which can impact on seeking survivorship care due to constraints placed on discussions because it remains difficult to discuss ‘cancer’ years later. Future research can evaluate if these findings are unique to Latino childhood cancer survivors or are found in other populations of AYA cancer survivors transitioning to adult-centered healthcare. This community-based participatory research collaboration also highlights the opportunity to learn about the needs of childhood cancer survivors from the lens of community leaders serving culturally diverse populations. Copyright © 2010 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
35. Late Morbidity After Successful Treatment of Children with Cancer.
- Author
-
Bhatia, Smita and Constine, Louis S.
- Subjects
CHILDHOOD cancer ,CANCER treatment complications ,GROWTH of children ,CARDIOPULMONARY system ,DISEASES ,ENDOCRINE diseases ,KIDNEY diseases ,CANCER treatment - Abstract
Over the last 4 decades, there has been a tremendous improvement in survival of children diagnosed with cancer, with 5-year survival rates now averaging 80%. The rapidly growing population of childhood cancer survivors creates an obligation to understand the health and well being of these individuals. Use of cancer therapy at an early age can produce a large burden of morbidity, as demonstrated quite conclusively by the fact that approximately two thirds of these survivors will experience at least one late effect, and approximately one third will experience a late effect, that is, severe or life threatening. Long-term complications in childhood cancer survivors, such as impairment in growth and development, neurocognitive dysfunction, cardiopulmonary compromise, endocrine dysfunction, renal impairment, gastrointestinal dysfunction, musculoskeletal sequelae, and second cancers, are related not only to the specific therapy used, but may also be determined by individual host characteristics. This review provides an update of the known late effects observed in childhood cancer survivors to provide the rationale for evaluation of specific long-term problems in this growing population of individuals at risk for chronic health conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
36. Cancer Survivorship: A Pediatric Perspective.
- Author
-
LANDIER, WENDY and BHATIA, SMITA
- Subjects
CHILDHOOD cancer ,CANCER patients ,HEALTH of patients ,CANCER treatment ,THERAPEUTIC complications - Abstract
The last four decades have seen tremendous improvements in the survival of children diagnosed with cancer, with 5-year survival rates now at 80%. The burgeoning population of childhood cancer survivors creates an obligation to understand the health and well-being of these individuals. The use of cancer therapy at an early age can produce complications that may not become apparent until years later; it has been demonstrated quite conclusively that approximately two thirds of these survivors will experience at least one late effect and about one third will experience a late effect that is severe or life threatening. Long-term complications in childhood cancer survivors, such as impairment in growth and development, neurocognitive dysfunction, cardiopulmonary compromise, endocrine dysfunction, renal impairment, gastrointestinal dysfunction, musculoskeletal sequelae, and subsequent malignancies, are not only related to the specific therapy employed, but may also be determined by individual host characteristics. This review describes some of the known late effects described in childhood cancer survivors in order to suggest reasonable starting points for evaluation of specific long-term problems in this unique and growing population. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
37. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
- Author
-
Blanco, Javier G., Leisenring, Wendy M., Gonzalez-Covarrubias, Vanessa M., Kawashima, Toana I., Davies, Stella M., Relling, Mary V., Robison, Leslie L., Sklar, Charles A., Stovall, Marilyn, and Bhatia, Smita
- Subjects
GENETIC polymorphisms ,PHARMACODYNAMICS ,ANTHRACYCLINES ,CONGESTIVE heart failure ,METABOLITES ,CHILDHOOD cancer ,MULTIVARIATE analysis ,HEART failure ,OXIDOREDUCTASES ,RESEARCH funding ,TUMORS ,CASE-control method - Abstract
Background: Exposure to anthracyclines as part of cancer therapy has been associated with the development of congestive heart failure (CHF). The potential role of genetic risk factors in anthracycline-related CHF remains to be defined. Thus, in this study, the authors examined whether common polymorphisms in candidate genes involved in the pharmacodynamics of anthracyclines (in particular, the nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1 and the carbonyl reductase 3 gene CBR3) had an impact on the risk of anthracycline-related CHF.Methods: A nested case-control study was conducted within a cohort of 1979 patients enrolled in the Childhood Cancer Survivor Study who received treatment with anthracyclines and had available DNA. Thirty patients with CHF (cases) and 115 matched controls were genotyped for polymorphisms in NQO1 (NQO1*2) and CBR3 (the CBR3 valine [V] to methionine [M] substitution at position 244 [V244M]). Enzyme activity assays with recombinant CBR3 isoforms (CBR3 V244 and CBR3 M244) and the anthracycline substrate doxorubicin were used to investigate the functional impact of the CBR3 V244M polymorphism.Results: Multivariate analyses adjusted for sex and primary disease recurrence were used to test for associations between the candidate genetic polymorphisms (NQO1*2 and CBR3 V244M) and the risk of CHF. Analyses indicated no association between the NQO1*2 polymorphism and the risk of anthracycline-related CHF (odds ratio [OR], 1.04; P=.97). There was a trend toward an association between the CBR3 V244M polymorphism and the risk of CHF (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A). In line, recombinant CBR3 V244 (G allele) synthesized 2.6-fold more cardiotoxic doxorubicinol per unit of time than CBR3 M244 (A allele; CBR3 V244 [8.26+/-3.57 nmol/hour.mg] vs CBR3 M244 [3.22+/-0.67 nmol/hour.mg]; P=.01).Conclusions: The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites. Larger confirmatory case-control studies are warranted. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
38. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.
- Author
-
Armenian, Saro H, Hudson, Melissa M, Lindenfeld, Lanie, Chen, Sitong, Chow, Eric J, Colan, Steven, Collier, Willem, Su, Xiaohong, Marcus, Edward, Echevarria, Meagan, Iukuridze, Aleksi, Robison, Leslie L, Wong, F Lennie, Chen, Ming Hui, and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *CARVEDILOL , *CANCER survivors , *PLACEBOS , *HEART failure patients - Abstract
Carvedilol improves cardiac function in patients with heart failure but remains untested as cardioprotective therapy in long-term childhood cancer survivors (ie, those who have completed treatment for childhood cancer and are in remission) at risk for heart failure due to high-dose anthracycline exposure. We aimed to evaluate the activity and safety of low-dose carvedilol for heart failure risk reduction in childhood cancer survivors at highest risk for heart failure. PREVENT-HF was a randomised, double-blind, phase 2b trial done at 30 hospitals in the USA and Canada. Patients were eligible if they had any cancer diagnosis that resulted in at least 250 mg/m2 cumulative exposure to anthracycline by age 21 years; completed their cancer treatment at least 2 years previously; an ejection fraction of at least 50% or fractional shortening of at least 25%, or both; and bodyweight of at least 40 kg. Patients were randomly assigned (1:1) with automated computer-generated permuted block randomisation (block size of 4), stratified by age at diagnosis, time since diagnosis, and history of chest-directed radiotherapy, to carvedilol (up-titrated from 3·125 g per day to 12·5 mg per day) or placebo orally for 2 years. Participants, staff, and investigators were masked to study group allocation. The primary endpoint was to establish the effect of carvedilol on standardised left ventricular wall thickness–dimension ratio Z score (LVWT/Dz). Treatment effects were analysed with a linear mixed-effects model for normally distributed data with a linear time effect and testing the significance of treatment*time interaction in the modified intention-to-treat (mITT) cohort (ie, all randomly assigned participants who had a baseline and at least one subsequent echocardiogram measurement). Safety was assessed in the ITT population (ie, all randomly assigned participants). This trial was registered with ClinicalTrials.gov , NCT027175073 , and enrolment and follow-up are complete. Between July 3, 2012, and June 22, 2020, 196 participants were enrolled, of whom 182 (93%) were eligible and randomly assigned to either carvedilol (n=89) or placebo (n=93; ITT population). Median age was 24·7 years (IQR 19·6–36·6), 91 (50%) participants were female, 91 (50%) were male, and 119 (65%) were non-Hispanic White. As of data cutoff (June 10, 2022), median follow-up was 725 days (IQR 378–730). 151 (n=75 in the carvedilol group and n=76 in the placebo group) of 182 participants were included in the mITT population, among whom LVWT/Dz was similar between the two groups (−0·14 [95% CI −0·43 to 0·16] in the carvedilol group vs −0·45 [−0·77 to −0·13] in the placebo group; difference 0·31 [95% CI –0·10 to 0·73]; p=0·14). Two (2%) of 89 patients in the carvedilol group two adverse events of grade 2 or higher (n=1 shortness of breath and n=1 arthralgia) and none in the placebo group. There were no adverse events of grade 3 or higher and no deaths. Low-dose carvedilol appears to be safe in long-term childhood cancer survivors at risk for heart failure, but did not result in significant improvement of LVWT/Dz compared with placebo. These results do not support the use of carvedilol for secondary heart failure prevention in anthracycline-exposed childhood cancer survivors. National Cancer Institute, Leukemia & Lymphoma Society, St Baldrick's Foundation, Altschul Foundation, Rally Foundation, American Lebanese Syrian Associated Charities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort.
- Author
-
Im, Cindy, Lu, Zhe, Mostoufi-Moab, Sogol, Delaney, Angela, Yu, Lin, Baedke, Jessica L, Han, Yutong, Sapkota, Yadav, Yasui, Yutaka, Chow, Eric J, Howell, Rebecca M, Bhatia, Smita, Hudson, Melissa M, Ness, Kirsten K, Armstrong, Gregory T, Nathan, Paul C, and Yuan, Yan
- Subjects
- *
CHILDHOOD cancer , *CANCER survivors , *PREDICTION models , *RECEIVER operating characteristic curves , *RADIATION dosimetry - Abstract
Female survivors of childhood cancer are at risk for primary ovarian insufficiency (POI), defined as the cessation of gonadal function before the age of 40 years. We aimed to develop and validate models to predict age-specific POI risk among long-term survivors of childhood cancer. To develop models to predict age-specific POI risk for the ages of 21–40 years, we used data from the Childhood Cancer Survivor Study (CCSS). Female survivors aged 18 years or older at their latest follow-up, with self-reported menstrual history information and free of subsequent malignant neoplasms within 5 years of diagnosis, were included. We evaluated models that used algorithms based on statistical or machine learning to consider all predictors, including cancer treatments. Cross-validated prediction performance metrics (eg, area under the receiver operating characteristic curve [AUROC]) were compared to select the best-performing models. For external validation of the models, we used data from 5-year survivors in the St Jude Lifetime Cohort (SJLIFE) with ovarian status clinically ascertained using hormone measurements (menopause defined by follicle stimulating hormone >30 mIU/mL and oestradiol <17 pg/mL) and medical chart or questionnaire review. We also evaluated an SJLIFE-based polygenic risk score for POI among 1985 CCSS survivors with genotype data available. 7891 female CCSS survivors (922 with POI) were included in the development of the POI risk prediction model, and 1349 female SJLIFE survivors (101 with POI) were included in the validation study. Median follow-up from cancer diagnosis was 23·7 years (IQR 18·3–30·0) in CCSS and 15·1 years (10·4–22·9) in SJLIFE. Between the ages of 21 and 40 years, POI prevalence increased from 7·9% (95% CI 7·3–8·5) to 18·6% (17·3–20·0) in CCSS and 7·3% (5·8–8·9) to 14·9% (11·6–19·1) in SJLIFE. Age-specific logistic regression models considering ovarian radiation dosimetry or prescribed pelvic and abdominal radiation dose, along with individual chemotherapy predictors, performed well in CCSS. In the SJLIFE validation, the prescribed radiation dose model performed well (AUROC 0·88–0·95), as did a simpler model that considered any exposures to pelvic or abdominal radiotherapy or alkylators (0·82–0·90). Addition of the polygenic risk predictor significantly improved the average positive predictive value (from 0·76 [95% CI 0·63–0·89] to 0·87 [0·80–0·94]; p=0·029) among CCSS survivors treated with ovarian radiation and chemotherapy. POI risk prediction models using treatment information showed robust prediction performance in adult survivors of childhood cancer. Canadian Institutes of Health Research, US National Cancer Institute. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Second primary cancers in survivors of childhood cancer.
- Author
-
Oeffinger, Kevin C. and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *CANCER relapse , *CANCER treatment complications , *ANTINEOPLASTIC agents , *DRUG side effects , *CANCER of unknown primary origin - Abstract
The authors argue in support of the need to recognize second primary cancers in childhood cancer survivors. A research discovered that childhood cancer survivors have two to three fold greater risk of developing second primary cancer compared to the general population. According to the authors, the late mortality and chronic morbidity associated with second primary cancer led to recommendations for cancer screening based on exposure to treatments. They emphasize the need for more research on cancer, and the need to promote and enhance cancer screening.
- Published
- 2009
- Full Text
- View/download PDF
41. Expert Panel Endorsed Quality Metrics for End-of-Life Care for Children with Cancer: Results of a Modified Delphi Panel (CS203A).
- Author
-
Johnston, Emily, Martinez, Isaac, and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *TERMINAL care , *DELPHI method , *HOSPICE nurses , *SOCIAL services - Published
- 2020
- Full Text
- View/download PDF
42. Impaired fertility linked to radiation dose in survivors of childhood cancer.
- Author
-
Bhatia, Smita
- Subjects
- *
INFERTILITY , *CHILDHOOD cancer , *RADIOTHERAPY , *CANCER patients , *CANCER in women , *PSYCHOLOGY - Abstract
The article provides information on a study which examined the link between impaired fertility and radiation dose in survivors of childhood cancer, conducted by researchers from Saint Jude Children's Research Hospital. Using data from the Childhood Cancer Survivor Study, the researchers headed by physician Daniel M. Green, found that ovarian radiation dose and increasing alkylating agent exposure may be contributors to impaired fertility in women who survived cancer as a child.
- Published
- 2008
43. Generalizability of "GWAS Hits" in Clinical Populations: Lessons from Childhood Cancer Survivors.
- Author
-
Im, Cindy, Qin, Na, Wang, Zhaoming, Qiu, Weiyu, Howell, Carrie R., Sapkota, Yadav, Moon, Wonjong, Chemaitilly, Wassim, Gibson, Todd M., Mulrooney, Daniel A., Ness, Kirsten K., Wilson, Carmen L., Morton, Lindsay M., Armstrong, Gregory T., Bhatia, Smita, Zhang, Jinghui, Hudson, Melissa M., Robison, Leslie L., and Yasui, Yutaka
- Subjects
- *
CANCER survivors , *CHILDHOOD cancer , *COMPLEMENTARY DNA , *DNA methylation , *FERTILITY preservation , *CANCER treatment - Abstract
With mounting interest in translating genome-wide association study (GWAS) hits from large meta-analyses (meta-GWAS) in diverse clinical settings, evaluating their generalizability in target populations is crucial. Here, we consider long-term survivors of childhood cancers from the St. Jude Lifetime Cohort Study, and we show the limited generalizability of 1,376 robust SNP associations reported in the general population across 12 complex anthropometric and cardiometabolic phenotypes (n = 2,231; observed-to-expected replication ratio = 0.70, p = 6.2 × 10−8). An examination of five comparable phenotypes in a second independent cohort of survivors from the Childhood Cancer Survivor Study corroborated the overall limited generalizability of meta-GWAS hits to survivors (n = 4,212; observed-to-expected replication ratio = 0.55, p = 5.6 × 10−15). Finally, in direct comparisons of survivor samples against independent equivalently powered general population samples from the UK Biobank, we consistently observed lower meta-GWAS hit replication rates and poorer polygenic risk score predictive performance in survivor samples for multiple phenotypes. As a possible explanation, we found that meta-GWAS hits were less likely to be replicated in survivors who had been exposed to cancer therapies that are associated with phenotype risk. Examination of complementary DNA methylation data in a subset of survivors revealed that treatment-related methylation patterns at genomic sites linked to meta-GWAS hits may disrupt established genetic signals in survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Disparities in End-of-Life Care in Children Dying of Cancer in Alabama (RP419).
- Author
-
Davis, Elizabeth, Martinez, Isaac, Bhatia, Smita, and Johnston, Emily
- Subjects
- *
CHILD care , *TERMINAL care , *CHILDHOOD cancer - Published
- 2020
- Full Text
- View/download PDF
45. Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.
- Author
-
Holmqvist, Anna Sällfors, Yanjun Chen, Wu, Jessica, Battles, Kevin, Bhatia, Ravi, Francisco, Liton, Hageman, Lindsey, Kung, Michelle, Ness, Emily, Parman, Mariel, Salzman, Donna, Winther, Jeanette Falck, Rosenthal, Joseph, Forman, Stephen J., Weisdorf, Daniel J., Arora, Mukta, Armenian, Saro H., and Bhatia, Smita
- Subjects
- *
BONE marrow transplantation , *CHILDHOOD cancer , *CANCER relapse , *CANCER patients , *MORTALITY - Abstract
Autologous blood or marrow transplantation (BMT) is a curative option for several types of childhood cancer. However, there is little information regarding the risk of late mortality. We examined all-cause mortality, relapse-related mortality (RRM), and nonrelapse-related mortality (NRM) in 2-year survivors of autologous BMT performed before age 22 between 1980 and 2010 at 1 of 2 US transplant centers. Vital status information was collected using medical records, National Death Index, and Accurint databases. Overall survival was calculated using Kaplan-Meier techniques. Cumulative incidence of mortality used competing risk methods. Standardized mortality ratio (SMR) was calculated using age-, sex-, and calendar-specific mortality rates from Centers for Disease Control and Prevention. Cox regression analysis was used to determine predictors of all-cause late mortality. Among the 345 2-year survivors, 103 deaths were observed, yielding an overall survival of 70.3% 15 years post-BMT. The leading causes of death included primary disease (50.0%), subsequent neoplasm (21.4%), and infection (18.2%). Overall, the cohort was at a 22-fold increased risk of late mortality (SMR, 21.8; 95% Cl, 17.9-26.3), compared with the general population. Mortality rates remained elevated among the 10-year survivors (SMR, 20.6; 95% Cl, 9.9-37.2) but approached those of the general population £15 years post-BMT. The 10-year cumulative incidence of RRM (14.3%) exceeded that of NRM (10.4%). The 10-year cumulative mortality rate declined over time (<1990, 35.1%; 1990-1999, 25.6%; 2000-2010, 21.8%; P = .05). In conclusion, childhood autologous BMT recipients have an increased risk of late mortality, compared with the general population. The late mortality rates have declined over the past 3 decades. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.
- Author
-
Chow, Eric J., Anderson, Lynnette, Baker, K. Scott, Bhatia, Smita, Guilcher, Gregory M.T., Huang, Jennifer T., Pelletier, Wendy, Perkins, Joanna L., Rivard, Linda S., Schechter, Tal, Shah, Ami J., Wilson, Karla D., Wong, Kenneth, Grewal, Satkiran S., Armenian, Saro H., Meacham, Lillian R., Mulrooney, Daniel A., and Castellino, Sharon M.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CHILDHOOD cancer , *CURATIVE medicine , *HEMATOLOGIC malignancies , *COMPARATIVE studies , *CANCER treatment , *DISEASE risk factors - Abstract
Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high-risk hematologic malignancies, solid tumors, and, increasingly, nonmalignant diseases. Given improvements in care, there are a growing number of long-term survivors of pediatric HCT. Compared with childhood cancer survivors who did not undergo transplantation, HCT survivors have a substantially increased burden of serious chronic conditions and impairments involving virtually every organ system and overall quality of life. This likely reflects the joint contributions of pretransplantation treatment exposures and organ dysfunction, the transplantation conditioning regimen, and any post-transplantation graft-versus-host disease (GVHD). In response, the Children's Oncology Group (COG) has created long-term follow-up guidelines ( www.survivorshipguidelines.org ) for survivors of childhood, adolescent, and young adult cancer, including those who were treated with HCT. Guideline task forces, consisting of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other health care professionals, and patient advocates systematically reviewed the literature with regards to late effects after childhood cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided herein is an organ system–based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those who underwent transplantation for nonmalignant diseases, and those with a history of chronic GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.
- Author
-
Armstrong, Gregory T., Yan Chen, Yasui, Yutaka, Leisenring, Wendy, Gibson, Todd M., Mertens, Ann C., Stovall, Marilyn, Oeffinger, Kevin C., Bhatia, Smita, Krull, Kevin R., Nathan, Paul C., Neglia, Joseph P., Green, Daniel M., Hudson, Melissa M., Robison, Leslie L., and Chen, Yan
- Subjects
- *
CHILDHOOD cancer , *CANCER-related mortality , *CANCER treatment , *HEALTH of cancer patients , *RADIOTHERAPY , *TUMOR treatment , *AGE factors in disease , *GLIOMAS , *HODGKIN'S disease , *LONGITUDINAL method , *LYMPHOBLASTIC leukemia , *MORTALITY , *NEPHROBLASTOMA , *RESEARCH funding , *TUMORS , *DISEASE relapse , *DISEASE incidence , *DISEASE progression - Abstract
Background: Among patients in whom childhood cancer was diagnosed in the 1970s and 1980s, 18% of those who survived for 5 years died within the subsequent 25 years. In recent decades, cancer treatments have been modified with the goal of reducing life-threatening late effects.Methods: We evaluated late mortality among 34,033 patients in the Childhood Cancer Survivor Study cohort who survived at least 5 years after childhood cancer (i.e., cancer diagnosed before the age of 21 years) for which treatment was initiated during the period from 1970 through 1999. The median follow-up was 21 years (range, 5 to 38). We evaluated demographic and disease factors that were associated with death from health-related causes (i.e., conditions that exclude recurrence or progression of the original cancer and external causes but include the late effects of cancer therapy) using cumulative incidence and piecewise exponential models to estimate relative rates and 95% confidence intervals.Results: Of the 3958 deaths that occurred during the study period, 1618 (41%) were attributable to health-related causes, including 746 deaths from subsequent neoplasms, 241 from cardiac causes, 137 from pulmonary causes, and 494 from other causes. A reduction in 15-year mortality was observed for death from any cause (from 12.4% in the early 1970s to 6.0% in the 1990s, P<0.001 for trend) and from health-related causes (from 3.5% to 2.1%, P<0.001 for trend). These reductions were attributable to decreases in the rates of death from subsequent neoplasm (P<0.001), cardiac causes (P<0.001), and pulmonary causes (P=0.04). Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic leukemia (85% in the 1970s, 51% in the 1980s, and 19% in the 1990s), of abdominal radiotherapy for Wilms' tumor (78%, 53%, and 43%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), and of anthracycline exposure. Reduction in treatment exposure was associated with reduced late mortality among survivors of acute lymphoblastic leukemia and Wilms' tumor.Conclusions: The strategy of lowering therapeutic exposure has contributed to an observed decline in late mortality among 5-year survivors of childhood cancer. (Funded by the National Cancer Institute and the American Lebanese-Syrian Associated Charities.). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
48. Genetically Mediated Nf1 Loss in Mice Promotes Diverse Radiation-Induced Tumors Modeling Second Malignant Neoplasms.
- Author
-
Choi, Grace, Huang, Brian, Pinarbasi, Emile, Braunstein, Steve E., Horvai, Andrew E., Kogan, Scott, Bhatia, Smita, Faddegon, Bruce, and Nakamura, Jean L.
- Subjects
- *
CANCER patients , *CHILDHOOD cancer , *CANCER treatment , *MEDICAL radiology , *RADIATION carcinogenesis - Abstract
Second malignant neoplasms (SMN) are therapy-induced malignancies and a growing problem in cancer survivors, particularly survivors of childhood cancers. The lack of experimental models of SMNs has limited understanding of their pathogenesis. It is currently not possible to predict or prevent this devastating late complication. Individuals with neurofibromatosis I (NF1) are at increased risk of developing therapy-induced cancers for unclear reasons. To model SMNs, we replicated clinical radiotherapy and delivered fractionated abdominal irradiation to Nf1+/- and wild-type mice. Similar to irradiated cancer survivors, irradiated wildtype and Nf1+/- mice developed diverse in-field malignancies. In Nf1+/- mice, fractionated irradiation promoted both classical NF1-associated malignancies and malignancies unassociated with the NF1 syndrome but typical of SMNs. Nf1 heterozygosity potentiated the mutagenic effects of irradiation, as evidenced by the significantly reduced survival after irradiation and tumor development that was often characterized by synchronous primary tumors. Interestingly, diverse radiation-induced tumors arising in wild-type and Nf1+/- mice shared a genetic signature characterized by monoallelic loss of Nf1 and the adjacent Trp53 allele. These findings implicate Nf1 loss as mediating tumorigenesis in a broad range of cell types and organs extending beyond the classical NF1 tumor histologies. Examining clinical SMN samples, we found LOH of NF1 in SMNs from non-NF1 patients. Nf1 heterozygosity confers broad susceptibility to genotoxin-induced tumorigenesis, and this paradigm serves as an experimental platform for future studies of SMNs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
49. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines
- Author
-
Pulsipher, Michael A., Skinner, Roderick, McDonald, George B., Hingorani, Sangeeta, Armenian, Saro H., Cooke, Kenneth R., Gracia, Clarisa, Petryk, Anna, Bhatia, Smita, Bunin, Nancy, Nieder, Michael L., Dvorak, Christopher C., Sung, Lillian, Sanders, Jean E., Kurtzberg, Joanne, and Baker, K. Scott
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *MEDICAL screening , *CHILDHOOD cancer , *GUIDELINES , *FOLLOW-up studies (Medicine) - Abstract
Existing standards for screening and management of late effects occurring in children who have undergone hematopoietic cell transplantation (HCT) include recommendations from pediatric cancer networks and consensus guidelines from adult-oriented transplantation societies applicable to all HCT recipients. Although these approaches have significant merit, they are not pediatric HCT-focused, and they do not address post-HCT challenges faced by children with complex nonmalignant disorders. In this article we discuss the strengths and weaknesses of current published recommendations and conclude that pediatric-specific guidelines for post-HCT screening and management would be beneficial to the long-term health of these patients and would promote late effects research in this field. Our panel of late effects experts also provides recommendations for follow-up and therapy of selected post-HCT organ and endocrine complications in pediatric patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).
- Author
-
Armenian, Saro H., Can-Lan Sun, Kawashima, Toana, Arora, Mukta, Leisenring, Wendy, Sklar, Charles A., Baker, K. Scott, Francisco, Liton, Berano The, Jennifer, Mills, George, Wong, F. Lennie, Rosenthal, Joseph, Diller, Lisa R., Hudson, Melissa M., Oeffinger, Kevin C., Forman, Stephen J., Robison, Leslie L., and Bhatia, Smita
- Subjects
- *
CHILDHOOD cancer , *HEMATOLOGY , *BONE marrow transplantation , *SIBLINGS , *CHRONIC diseases - Abstract
HSCT is being increasingly offered as a curative option for children with hematologic malignancies. Although survival has improved, the long-term morbidity ascribed to the HSCT procedure is not known. We compared the risk of chronic health conditions and adverse health among children with cancer treated with HSCT with survivors treated conventionally, as well as with sibling controls. HSCT survivors were drawn from BMTSS (N = 145), whereas conventionally treated survivors (N = 7207) and siblings (N = 4020) were drawn from CCSS. Self- reported chronic conditions were graded with CTCAEv3.0. Fifty-nine percent of HSCT survivors reported ≥ 2 conditions, and 25.5% reported severe/life-threatening conditions. HSCT survivors were more likely than sibling controls to have severe/life-threatening (relative risk [RR] = 8.1, P < .01)and 2 or more(RR = 5.7, p < .01) conditions, as well as functional impairment (RH = 7.7, p < .01) and activity limitation (RR = 6.3, p < .01). More importantly, compared with CCSS survivors, BMTSS survivors demonstrated significantly elevated risks (severe/life-threatening conditions: RR = 3.9, p < .01; multiple conditions: RR = 2.6, p < .01; functional impairment: RR = 3.5, p < .01; activity limitation: AR = 5.8, p < .01). Unrelated donor HSCT recipients were at greatest risk. Childhood HSCT survivors carry a significantly greater burden of morbidity not only compared with noncancer populations but also compared with conventionally treated cancer patients, providing evidence for close monitoring of this high-risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.